Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with… Feb 17, 2022
Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program Jun 14, 2021
Mindset Pharma Announces Strong Confirmation of In Vivo Proof-of-Concept Across Its Entire New Drug Program Portfolio Apr 20, 2021
